Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 14/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 12/20 | 0.41 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.36 |
| ▸ | LAP3 | P28838 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30782827 | 0.87 | BRD4 (0.36) | UCHL1USP30GPR119 | |
| SCHEMBL30782918 | 0.86 | HTR6 (0.37) | UCHL1GPR119 | |
| SCHEMBL31664596 | 0.85 | BRD4 (0.35) | CYP11B2CYP11B1UCHL1USP30HRH3 | |
| SCHEMBL30782832 | 0.83 | GPR119 (0.36) | CYP11B2CYP11B1GPR119 | |
| SCHEMBL30782831 | 0.83 | GPR119 (0.36) | CYP11B2CYP11B1GPR119 | |
| SCHEMBL31664592 | 0.83 | JAK2 (0.35) | CYP11B2CYP11B1UCHL1USP30HRH3 | |
| SCHEMBL30782830 | 0.83 | JAK2 (0.35) | CYP11B2CYP11B1UCHL1USP30HRH3 | |
| SCHEMBL22814012 | 0.79 | ADRA2A (0.39) | GPR119 | |
| SCHEMBL30782865 | 0.78 | UCHL1 (0.38) | CYP11B2CYP11B1UCHL1 | |
| SCHEMBL30782913 | 0.73 | CYP11B2 (0.46) | CYP11B2CYP11B1HRH3LAP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388558-A1 | COMPOUNDS FOR THE TREATMENT OF A CENTRAL NERVOUS SYSTEM DISEASE OR DISORDER | CORETERRA THERAPEUTICS INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-20250304546-A1 | COMPOUNDS FOR THE TREATMENT OF A CENTRAL NERVOUS SYSTEM DISEASE OR DISORDER | CORETERRA THERAPEUTICS, INC. | 2025-10-02 | — | — | US | disclosed |
| EP-4593954-A1 | COMPOUNDS FOR THE TREATMENT OF A CENTRAL NERVOUS SYSTEM DISEASE OR DISORDER | PGI Drug Discovery LLC (US) | 2025-08-06 | — | — | EP | disclosed |
| US-20250243173-A1 | COMPOUNDS FOR THE TREATMENT OF A CENTRAL NERVOUS SYSTEM DISEASE OR DISORDER | CORETERRA THERAPEUTICS, INC. | 2025-07-31 | — | — | US | disclosed |
| US-20250236602-A1 | COMPOUNDS FOR THE TREATMENT OF A CENTRAL NERVOUS SYSTEM DISEASE OR DISORDER | CORETERRA THERAPEUTICS, INC. | 2025-07-24 | — | — | US | disclosed |
| US-20250129035-A1 | COMPOUNDS FOR THE TREATMENT OF A CENTRAL NERVOUS SYSTEM DISEASE OR DISORDER | CORETERRA THERAPEUTICS, INC. | 2025-04-24 | — | — | US | disclosed |
| WO-2024073383-A1 | COMPOUNDS FOR THE TREATMENT OF A CENTRAL NERVOUS SYSTEM DISEASE OR DISORDER | PGI DRUG DISCOVERY LLC (US) | 2024-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250129035-A1 | COMPOUNDS FOR THE TREATMENT OF A CENTRAL NERVOUS SYSTEM DISEASE OR DISORDER | PMP22, INA, SLC18A2 | CYP11B2 387/4885CYP11B1 732/4885UCHL1 2325/4885 |
| US-20250236602-A1 | COMPOUNDS FOR THE TREATMENT OF A CENTRAL NERVOUS SYSTEM DISEASE OR DISORDER | PMP22, INA, SLC18A2 | CYP11B2 387/4885CYP11B1 732/4885UCHL1 2325/4885 |
| US-20250304546-A1 | COMPOUNDS FOR THE TREATMENT OF A CENTRAL NERVOUS SYSTEM DISEASE OR DISORDER | PMP22, INA, SLC18A2 | CYP11B2 387/4885CYP11B1 732/4885UCHL1 2325/4885 |
| US-20250243173-A1 | COMPOUNDS FOR THE TREATMENT OF A CENTRAL NERVOUS SYSTEM DISEASE OR DISORDER | PMP22, INA, SLC18A2 | CYP11B2 387/4885CYP11B1 732/4885UCHL1 2325/4885 |
| US-20250388558-A1 | COMPOUNDS FOR THE TREATMENT OF A CENTRAL NERVOUS SYSTEM DISEASE OR DISORDER | GRIN2C, SLC6A1, CLIC1 | CYP11B2 217/4885CYP11B1 241/4885UCHL1 2633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.